ATLANTA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that it will report second quarter 2024 financial results on Thursday, August 8, 2024 before the open of the financial markets.

Thu, Aug. 01, 2024

- Virios projects releasing top line results from this groundbreaking Proof of Concept study in October 2024 - - Published data indicates increased Epstein-Barr herpes virus in Long-COVID patients, highlighting potential for antiviral therapy to treat fatigue and other Long-COVID symptoms - ATLANTA, July 23, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced that the Bateman Horne Center (“BHC”) has completed enrollment in its investigator-initiated, proof of concept LC study. Top line data from this study are projected to be released in October 2024.

Tue, Jul. 23, 2024

ATLANTA, May 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced the closing of its previously announced public offering of 8,500,000 shares of its common stock at a public offering price of $0.20 per share. Gross proceeds from the offering are $1.7 million before deducting placement agent fees and offering expenses. Virios Therapeutics intends to use the net proceeds of the offering to commence preparatory activities for its planned IMC-2 Long-COVID Phase 2b study and for general corporate purposes.

Wed, May. 22, 2024

U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 0.5% on Monday. Following the market opening Monday, the Dow traded down 0.19% to 39,925.91 while the NASDAQ rose 0.50% to 16,769.45. The S&P 500 also rose, gaining, 0.19% to 5,313.25. Check This Out: Top 3 Financial Stocks That Are Set To Fly This Quarter Information technology shares rose by 0.9% on Monday. In trading on Monday, real estate shares fell by 0.6%. Shares of The company posted revenue growth of 36.4% year-on-year to $3.55 billion, missing the analyst consensus estimate of $3.84 billion. Adjusted net earnings per ADS was 17 cents missed the analyst consensus estimate of 35 cents. GT Biopharma, Inc. GTBP+161.4%+ Free Alerts shares shot up 142% to $7.54. GT Biopharma, last week, posted a narrower-than-expected quarterly loss. Shares of Tantech Holdings Ltd TANH+79.5%+ Free Alerts got a boost, surging 119% to $1.44. MultiMetaVerse Holdings Limited MMV+187.8%+ Free Alerts shares were also up, gaining 102% to $1.25. MultiMetaVerse Holdings signed a non-binding term sheet to acquire 100% of Bowong Technology (Shenzhen) Co., Ltd. and its subsidiaries. Virios Therapeutics, Inc. VIRI-47.9%+ Free Alerts shares dropped 49% to $0.1790 after the company priced a $1.7 million pubic offering of 8.5 million shares of common stock at $0.20 per share. Shares of Akoustis Technologies, Inc. AKTS-44.7%Get Free Report were down 47% to $0.1899 after Qorvo won a jury verdict against the company in a trade secret misappropriation and patent infringement case. Jaguar Health, Inc JAGX-43.9%Get Free Report was down, falling 44% to $0.1457 after the company announced a 1-for-60 reverse stock split. Also Check This Out: This Analyst With 85% Accuracy Rate Sees Around 8% Upside In NVIDIA – Here Are 5 Stock Picks For Last Week From Wall Street’s Most Accurate Analysts In commodity news, oil traded down 0.4% to $79.74 while gold traded up 0.8% at $2,436.90. Silver traded up 1.9% to $31.84 on Monday, while copper rose 0.7% to $5.0860. European shares were higher today. The eurozone's STOXX 600 gained 0.2%, Germany's DAX rose 0.4% and France's CAC 40 climbed 0.5%. Spain's IBEX 35 Index rose 0.2%, while London's FTSE 100 rose 0.3%. Spain’s consumer confidence indicator climbed to 84.5 in April compared to 82.5 in March. The construction output in Italy rose by 3.8% year-over-year in March. Asian markets closed higher on Monday, with Japan's Nikkei gaining 0.73%, China's Composite Index climbing 0.54%, Hong Kong's Hang Seng Index gaining 0.42% and India's S&P BSE Sensex gaining 0.46%. Hong Kong's unemployment rate came in unchanged at 3% in the three months ending April 2024. Malaysia’s trade surplus shrank to MYR 7.7 billion in April from MYR 12.6 billion in the year-ago month. The People’s Bank of China held key lending rates at the recent fixing. No major economic reports will be released today. Now Read This: Insiders Buying Sempra And 2 Other Stocks

Mon, May. 20, 2024

Virios Therapeutics (NASDAQ: VIRI ) stock is falling on Monday after the development-stage biotechnology company announced the pricing of a public offering for its shares. Virios Therapeutics is selling 8.5 million shares of VIRI stock at a price of 20 cents per share.

Mon, May. 20, 2024